Lundbeck
Also known as: H. Lundbeck A/S | H. Lundbeck A/S, TEVA | LuncbeckClinicalTrials@Lundbeck.com | Lundbech Foundation | Lundbeck Canada Inc. | LundbeckClinicalTrials.com | LundbeckClinicalTrials@lundbeck.com | LundbeckClinicalTrials@Lundbeck.com | Lundbeck Foundation | Lundbeck France | Lundbeck GmbH, Ericusspitze 2, 20457 Hamburg | LUNDBECK INC | Lundbeck Israel | Lundbeck Italia S.p.A. | Lundbeck Japan K. K. | Lundbeck LLC | LUNDBECK NA LTD | Lundbeck Northera Ltd. | LUNDBECK PHARMS LLC | Lundbeck Seattle BioPharmaceuticals, Inc.
Highest phase reached
Phase 4
First clinical trial
Nov 1, 1989First marketed drug
Jan 9, 1962First NDA
Jan 9, 1962Last known activity
Dec 5, 2024
Timeline
1910s
- Jul 1, 1915
Lundbeck— Founded
2000s
- Mar 6, 2003
Synaptic Pharmaceutical Corporation— Acquired
- Dec 12, 2006
Saegis Pharmaceuticals— Acquired
- Mar 19, 2009
Ovation Pharmaceuticals— Acquired
- Aug 21, 2009
vigabatrin— NDA Organization
2010s
- Jun 23, 2014
Chelsea Therapeutics— Acquired
- Mar 16, 2018
Prexton Therapeutics— Acquired
- May 6, 2019
Abide Therapeutics— Acquired
- Sep 16, 2019
Alder Biopharmaceuticals— Acquired
2020s
- Feb 21, 2020
eptinezumab— Marketing Organization
- Feb 21, 2020
eptinezumab— NDA Secondary Org
- Oct 14, 2024
Longboard Pharmaceuticals— Acquired
Drugs by trial phase (122 distinct, 400 trials)
Phase 4 (26 own, 4 via acquisition)
Phase 3 (26 own, 0 via acquisition)
Phase 2 (10 own, 11 via acquisition)
Phase 1 (28 own, 2 via acquisition)
Indications
Approved for
Studied for
- Acute Coronary Syndrome
- Aggression
- Alcohol Drinking
- Alcoholism
- Alzheimer Disease
- Amyotrophic Lateral Sclerosis
- Anxiety Disorders
- Aphasia
- Aphasia, Primary Progressive
- Ascites
- Ataxia
- Atrophy
- Attention Deficit and Disruptive Behavior Disorders
- Attention Deficit Disorder with Hyperactivity
- Autism Spectrum Disorder
- Autistic Disorder
- Bipolar Disorder
- Body Weight Changes
- Central Nervous System Diseases
- Cerebellar Ataxia
- Cerebral Infarction
- Child Development Disorders, Pervasive
- Cluster Headache
- Cognition Disorders
- Cognitive Dysfunction
- Compulsive Behavior
- Compulsive Personality Disorder
- Conduct Disorder
- Coronary Artery Disease
- Coronary Disease
- Dementia
- Dementia, Vascular
- Depression
- Depressive Disorder
- Disease
- Drug-Related Side Effects and Adverse Reactions
- Drug Resistant Epilepsy
- Dyssomnias
- Epilepsia Partialis Continua
- Epilepsies, Myoclonic
- Epilepsies, Partial
- Epilepsy
- Epilepsy, Generalized
- Fatigue
- Fibrosis
- Friedreich Ataxia
- Frontotemporal Dementia
- Headache
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Huntington Disease
- Hyperalgesia
- Hyperkinesis
- Hypotension
- Hypotension, Orthostatic
- Impulsive Behavior
- Ischemia
- Lennox Gastaut Syndrome
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Lewy Body Disease
- Liver Cirrhosis
- Liver Cirrhosis, Alcoholic
- Liver Diseases
- Lymphoma
- Lymphoma, Non-Hodgkin
- Major Depressive Disorder
- Mental Disorders
- Migraine Disorders
- Mood Disorders
- Motor Neuron Disease
- Multiple Sclerosis
- Multiple System Atrophy
- Myelodysplastic Syndromes
- Nervous System Diseases
- Neurobehavioral Manifestations
- Obsessive-Compulsive Disorder
- Osteoarthritis
- Panic Disorder
- Parasomnias
- Parkinson Disease
- Parkinsonian Disorders
- Phobia, Social
- Pick Disease of the Brain
- Polyneuropathies
- Postoperative Nausea and Vomiting
- Postoperative Pain
- Postural Orthostatic Tachycardia Syndrome
- Preleukemia
- Psychomotor Agitation
- Psychotic Disorders
- Recurrence
- Renal Insufficiency
- Schizophrenia
- Sclerosis
- Seizures
- Shy-Drager Syndrome
Marketed drugs (7)
Subsidiaries (8 direct, 8 total across the full acquisition tree)
Recent trials (50)
- NCT06701526Lead sponsorPhase 4Dec 5, 2024
- NCT06706622OfficialPhase 3Dec 3, 2024
- NCT06706622Lead sponsorPhase 3Dec 3, 2024
- NCT06428838CollaboratorPhase 3Sep 30, 2024
- NCT06557850Lead sponsorPhase 1Sep 19, 2024
- NCT06578585Lead sponsorPhase 1Sep 13, 2024
- NCT06578585OfficialPhase 1Sep 13, 2024
- NCT06471829Lead sponsorPhase 2Jun 19, 2024
- NCT06337110Lead sponsorPhase 1Apr 10, 2024
- NCT06323928Lead sponsorPhase 2Apr 1, 2024
- NCT06258720OfficialPhase 1Mar 18, 2024
- NCT06258720Lead sponsorPhase 1Mar 18, 2024
- NCT06277609Lead sponsorPhase 1Feb 27, 2024
- NCT06077786Lead sponsorPhase 1Oct 13, 2023
- NCT06077786Study directorPhase 1Oct 13, 2023
Details
- Founded
- Copenhagen, DK Jul 1, 1915
- First NDA
- Jan 9, 1962
- Last known activity
- Dec 5, 2024
Designations held
- Orphan drug